Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study used R-language data mining to analyze patents of topical Chinese medicine for hair loss, identifying key medication patterns and ingredients in traditional formulations.

Finasteride's effectiveness on the frontal hair loss area is not well-studied or confirmed.

This systematic review suggests that turmeric and curcumin products, both oral and topical, may offer therapeutic benefits for various skin conditions, though further research is necessary to evaluate efficacy more thoroughly.

This article discusses various pruritic dermatoses that can occur during pregnancy, emphasizing the importance of physician skill in diagnosing and treating these conditions; it reports no new findings.

This article addresses an unusual side effect of azathioprine but provides no abstract or detailed results, focusing instead on a specific dermatological perspective.

GLP-1RA medications may increase the risk of hair loss, especially in non-diabetic people.

This study found that prolonged use of finasteride and dutasteride in young men with androgenic alopecia is linked to a decline in semen quality over time, particularly affecting sperm motility and DNA integrity, with dutasteride showing a slightly greater impact than finasteride.

GLP-1 receptor agonists may help or harm hair health, needing more research.

This study found that pulse corticosteroids effectively induce hair regrowth in alopecia areata, with betamethasone showing higher efficacy but more side effects, and treatment success varying depending on age, onset time, and disease type.

This study found that in 45-year-old German men, the use of metformin, insulin, and ACE inhibitors was associated with lower PSA levels, while low dose finasteride resulted in notable PSA decrease.

This case report suggests that Citalopram may cause reversible hair loss in some patients, as evidenced by hair regrowth after discontinuing the drug.

This study from years of treating hair loss in Japan reported various treatment outcomes: some patients showed improvement with manual treatment alone, others with added finasteride, some did not respond to either, and some maintained benefits even after stopping finasteride.

This review describes minoxidil's hair regrowth mechanism and discusses dermatological applications, but reports no new clinical results, emphasizing the need for regular use and addressing allergic reactions.

This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.

This review reports that nirmatrelvir-ritonavir has significant drug-drug interactions with many common dermatological medications, whereas molnupiravir may be an alternative therapy due to the absence of such interactions observed so far.

This case report describes a rare instance of gynecomastia in a male patient undergoing mirtazapine treatment for depression, suggesting the drug as a probable cause after ruling out other factors.

This study concluded that topical minoxidil could effectively accelerate nail growth in both healthy individuals and those with nail disorders, though the regimen might differ across these groups.

This study evaluated dermatologists' beliefs and counseling practices regarding finasteride's adverse effects, revealing that while 51% believed it could cause sexual side effects, fewer associated it with depression or infertility, highlighting a need for increased awareness and improved patient counseling.

In this study, data from the FAERS database indicated varied associations between certain medications and obstructive sleep apnea, with some biologics associated with a decreased risk of developing the condition.

This report describes a rare side effect of finasteride in a previously healthy 40-year-old male patient.

This study suggests that cutaneous adverse reactions to bortezomib and lenalidomide are more frequent than reported, impacting patients' quality of life and may require dermatological consultation for proper management.

In a mouse model, this study found that nano-sized molybdenum accelerated hair growth and reduced oxidative stress markers, with enhancements observed when combined with minoxidil. It suggests potential for this combination as a novel topical treatment for hair loss, pending further clinical validation.

This study observed that patients using a novel topical combination of finasteride and minoxidil for male androgenetic alopecia reported high satisfaction and good tolerance, with few side effects and no need for higher-level care, despite limitations such as retrospective data and no control group.

In this large retrospective study, patients using compounded topical finasteride and minoxidil through a telehealth platform for male androgenetic alopecia reported high satisfaction and low incidence of side effects, with no need for higher care or treatment discontinuation due to adverse reactions.

This review examines nonmalignant skin toxicities from immunosuppressive and transplant-related medications, emphasizing the need for effective identification and management by care providers; it presents no new research findings.

This article proposes naming the visual identification of androgenic alopecia in COVID-19 patients as the "Gabrin sign" to indicate higher risk for severe symptoms, but reports no new clinical results.

The conclusion is that combining social and cultural factors with pharmaceutical research could improve our understanding of how drugs work.

The document concludes that more research is needed to confirm if COVID-19 vaccines cause a type of hair loss called alopecia areata.

This article discusses the FDA approval of bremelanotide for premenopausal women with hypoactive sexual desire disorder and reports no clinical results.

In this case report, researchers documented a rare instance of trans-epidermal elimination of insulin formulation in a 45-year-old woman with diabetes, suggesting that insulin or its excipients may have caused a granulomatous reaction leading to skin lesions at injection sites and impaired diabetes control.